Meeting
2019 ASCO Annual Meeting
Eflapegrastim, a novel and potent long-acting GCSF for reducing chemotherapy-induced neutropenia: Integrated results from two phase III trials in breast cancer patients.
Authors
Lee S. Schwartzberg
University of Tennessee Health Sciences Center, Memphis, TN
Lee S. Schwartzberg , Gajanan Bhat , Jayaram S. Bharadwaj , Osama Hlalah , Alvaro Restrepo , Inderjit Mehmi , Shanta Chawla , Patrick Wayne Cobb
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer—Local/Regional/Adjuvant
Track
Breast Cancer
Sub Track
Adjuvant Therapy
Clinical Trial Registration Number
NCT02643420, NCT02953340
Citation
J Clin Oncol 37, 2019 (suppl; abstr 539)
DOI
10.1200/JCO.2019.37.15_suppl.539
Abstract #
539
Poster Bd #
31
Abstract Disclosures
Similar Posters
Poster
2019 Supportive Care in Oncology Symposium
Eflapegrastim, a novel, long-acting GCSF for reducing chemotherapy-induced neutropenia: Integrated results from two phase III trials in breast cancer patients.
First Author: Lee S. Schwartzberg
Poster
2021 ASCO Quality Care Symposium
Association of primary prophylactic (PP) granulocyte-colony stimulating factor (G-CSF) use with chemotherapy dose modifications and relative dose intensity (RDI) among breast cancer patients receiving high-risk regimens for febrile neutropenia (FN).
First Author: Jaime Shaw
Poster
2021 ASCO Annual Meeting
Chemotherapy induced profound neutropenia (PN) in patients (pt) with breast cancer (BC) after chemotherapy and plinabulin (Plin) plus pegfilgrastim (Peg) combination versus (vs) peg alone: Final phase 3 results from protective-2 (BPI-2358-106).
First Author: Yuankai Shi
Poster
2021 ASCO Annual Meeting
Clinical trial testing superiority of combination plinabulin (Plin) and pegfilgrastim (Peg) versus peg alone in breast cancer treated with high-risk febrile neutropenia risk chemotherapy (chemo): Final results of the phase 3 protective-2 in chemo-induced neutropenia (CIN) prevention.
First Author: Douglas W. Blayney